"10.1371_journal.pone.0085838","plos one","2014-01-22T00:00:00Z","Ji Eun Han; Seo Ri Wui; Kwang Sung Kim; Yang Je Cho; Wan Je Cho; Na Gyong Lee","Department of Bioscience & Biotechnology, College of Bioscience, Sejong University, Seoul, Republic of Korea; Research & Development Center, EyeGene, Seoul, Republic of Korea; Yonsei University Gangnam Severance Hospital, Seoul, Republic of Korea","Conceived and designed the experiments: JEH YJC WJC NGL. Performed the experiments: JEH SRW KSK WJC. Analyzed the data: JEH YJC NGL. Contributed reagents/materials/analysis tools: JEH SRW KSK YJC WJC NGL. Wrote the paper: JEH NGL.","NGL is an inventor of EyeGene-owned patents, and a stock holder and grant recipient of EyeGene. KSK and YJC are employees and stock holders of EyeGene, and inventors of EyeGene-owned patents. WJC serves as a consultant of EyeGene. dLOS described in this article has been patented (PCT/KR2005/002490, Adjuvant comprising oligonucleotide and non-toxic LPS; PCT/KR2011/009759, Vaccines capable of inducing enhanced immune responses) and is being developed as an adjuvant to an HPV vaccine, which is under phase I clinical study. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Ji Eun Han","JEH",6,TRUE,4,4,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
